

***Amendments to the Claims***

The listing of claims will replace all prior versions, and listings of claims in the application.

1-165. (cancelled)

166. (previously presented) An isolated peptide selected from the group consisting of:

CTCGSSDLY (SEQ ID NO:3591);

KTSEERSQPR (SEQ ID NO:3579);

QLFTFSPRR (SEQ ID NO:3581);

RMYVGGVEHR (SEQ ID NO:3582);

LIFCHSKKK (SEQ ID NO:3583);

GVAGALVAFK (SEQ ID NO:3584); and

TLGFGAYMSK (SEQ ID NO:3586).

167. (cancelled)

168. (previously presented) The peptide of claim 166, which is 10 amino acids in length.

169. (cancelled)

170. (currently amended) A CTL/HTL epitope conjugate, wherein the CTL epitope of said CTL/HTL epitope conjugate is the isolated peptide of claim 166; [[and]]

wherein said CTL epitope is linked to a non- HCV(Hepatitis C Virus)

HTL helper epitope[.]:

wherein said CTL epitope is linked to said non- HCV HTL epitope either directly or via a spacer at the amino or carboxy terminus of the CTL peptide;

and wherein said spacer is no more than six residues in length.

171-176. (cancelled)

177. (previously presented) A composition comprising the peptide of claim  
166 and a carrier.

178-246. (cancelled)

247. (New) A composition comprising the conjugate of claim 170 and a carrier.